Levobunolol and betaxolol. A double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure.
In a double-masked, randomized, controlled clinical trial, the authors evaluated the ocular hypotensive efficacy of twice-daily treatment with levobunolol (0.25 and 0.5%) and betaxolol (0.5%) in 85 patients with open-angle glaucoma or ocular hypertension. During the 3-month study, intraocular pressure (IOP) reductions in the two levobunolol groups were significantly greater than in the betaxolol group. From a mean baseline IOP of approximately 25 mmHg, overall mean reductions were 6.2 and 6.0 mmHg for the 0.25 and 0.5% levobunolol groups, respectively, and 3.7 mmHg for the betaxolol group. No clinically or statistically significant among-group differences were noted in the systemic safety variables evaluated. These data suggest that although all three treatments are effective, levobunolol provides a greater reduction in IOP than betaxolol.
Long
D A
DA
Loma Linda University School of Medicine, CA.
Johns
G E
GE
Mullen
R S
RS
Bowe
R G
RG
Alexander
D
D
Epstein
D L
DL
Weiss
M J
MJ
Masi
R J
RJ
Charap
A D
AD
Eto
C Y
CY
D015784:Betaxolol; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005901:Glaucoma / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D002040:Levobunolol / Q000627:therapeutic use*; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D011412:Propanolamines / Q000627:therapeutic use*; D014794:Visual Fields / Q000187:drug effects
D011412:Propanolamines; D002040:Levobunolol; D015784:Betaxolol